The phosphatidylinositol 3'-kinase pathway is a dominant growth factor- activated cell survival pathway in LNCaP human prostate carcinoma cells

Cancer Research

Volumn 59, Issue 12, 1999, Pages 2891-2897

  Lin, Jianqing ^a   Adam, Rosalyn M ^a   Santiestevan, Eric ^a   Freeman, Michael R ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANDROSTANOLONE; BICALUTAMIDE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; TRANSFORMING GROWTH FACTOR ALPHA;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL PROTECTION; CELL SURVIVAL; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROGENS; APOPTOSIS; CELL SURVIVAL; DIHYDROTESTOSTERONE; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; HUMANS; LIGANDS; MALE; PROSTATIC NEOPLASMS; PROTECTIVE AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0033564514     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Kyprianou, N. Apoptosis: therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer. World. J. Urology, 12: 299-303, 1994.
2. Berchem, G. J., Bosseler, M., Sugars, L. Y., Voeller, H. J., Zeitlin, S., and Gelmann, E. P. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res., 55: 735-738, 1995.
3. Raffo, A. J., Perlman, H., Chen, Min-Wei, Day, M. L., Streitman, J. S., and Buttyan, R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res., 55: 4438-4445, 1995.
4. Yao, R., and Cooper, G. M. Growth factor-dependent survival of rodent fibroblasts requires phosphatidylinositol 3-kinase but is independent of pp70S6K activity. Oncogene, 13: 343-351, 1996.
5. 1. FEBS Lett., 416: 243-246, 1997.
6. Kulik, G., Klippel, A., and Weber, M. J. Antiapoptotic signaling by the insulin-like growth factor 1 receptor, phosphatidylinositol 3-kinase, and Akt. Mol. Cell. Biol., 17: 1595-1606, 1997.
7. Parrizas, M., Saltiel, A. R., and LeRoth, D. Insulin-like growth factor-1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways. J. Biol. Chem., 272: 154-161, 1997.
8. Crowder, R. J., and Freeman, R. S. Phosphatidylinositol 3-kinase and Akt protein kinase are necessary and sufficient for the survival of nerve growth factor dependent sympathetic neurons. J. Neurosci., 18: 2933-2943, 1998.
9. Del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R., and Nunez, G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science (Washington DC), 278: 687-689, 1997.
10. Veldsholte, J., Berrevoets, C. A., Ris-Stalpers, C., Kuiper, G. G., Jenster, G., Trapman, J., Brinkman, A. O., and Mulder, E. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J. Steroid Biochem. Mol. Biol., 41: 665-669, 1992.
11. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning, A Laboratory Manual, Ed. 2, pp. 16.33-16.37. Cold Spring Harbor Laboratory Press, 1989.
12. Herrmann, M., Lorenz, H-M, Voll R., Grunke M., Woith, W, and Kalden J. R. A rapid and simple method for isolation of apoptotic DNA fragments. Nucleic Acids Res, 22: 5506-5507, 1994.
13. Whitman, M. C. Downes, P., Keeler, M., Keller, T., and Cantley, L. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature (Lond.), 332: 644-646, 1988.
14. Monfar, M., Lemon, K. P., Grammer, T. C., Cheatham, L., Chung, J., Vlahos, C. J., and Blenis, J. Activation of pp70/85 S6 kinases in interleukin-2-responsive lymphoid cells is mediated by phosphatidylinositol 3-kinase and inhibited by cyclic AMP. Mol. Cell. Biol., 15: 326-337, 1995.
15. Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., and Saltiel, A. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA, 92: 7686-7689, 1995.
16. De Bellis, A., Ghiandi, P., Comerci, A., Fiorelli, G., Grappone, C., Milani, S., Salerno, R., Marra, P., and Serio, M. Epidermal growth factor, epidermal growth factor receptor, and transforming growth factor-α in human hyperplastic prostate tissue: expression and cellular localization. J. Clin. Endocrinol. & Metabol., 81: 4148-4154, 1996.
17. Freeman, M. R., Paul, S., Kaefer, M., Ishikawa, M., Adam, R. M., Renshaw, A. A., Elenius, K., and Klagsbrun, M. Heparin-binding EGF-like growth factor in the human prostate: Synthesis predominantly by interstitial and vascular smooth muscle cells and action as a carcinoma cell mitogen. J. Cell. Biochem., 68: 328-338, 1998.
18. Soltoff, S. P., Carraway, K. L., III, Prigent, S. A., Gullick, W. G., and Cantley, L. C. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol. Cell. Biol., 14: 3550-3558, 1994.
19. Franke, T. F., Kaplan, D. R., and Cantley, L. C. PI3K: downstream AKTion blocks apoptosis. Cell, 88: 435-431, 1997.
20. Wu, J., Dent, P, Jelenek, T., Wolfman, A., Weber, M. J., and Sturgill, T. W. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′,5′-monophosphate. Science (Washington DC), 262: 988-990, 1993.
21. Fanger, G. R., Johnson, N. L., and Johnson, G. L. MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42. EMBO J., 16: 4961-4972, 1997.
22. Leung, H. Y., Weston, J., Gullick, W. J., and Williams, G. A potential autocrine loop between heregulin-α and erbB-3 receptor in human prostatic adenocarcinoma. Br. J. Urol., 79: 212-216, 1997.
23. Kazlauskas, A., and Cooper, J. A. Phosphorylation of the PDGF receptor β subunit creates a tight binding site for phosphatidylinositol 3 kinase. EMBO J., 9: 3279-3286, 1990.
24. Burgering, B. M., and Coffer, P. J. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature (Lond.), 376: 599-602, 1995.
25. Akimoto, K., Takahashi, R., Moriya, S., Nishioka, N., Takayanagi, J., Kimura, K., Fukui, Y., Osada, S, Mizyuno, K., Hirai, S., Kazlauskas, A., and Ohno, S. EGF or PDGF receptors activate atypical PKClambda through phosphatidylinositol 3-kinase. EMBO J., 15: 788-798, 1996.
26. Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M. E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 91: 231-241, 1997.
27. Skov, S., Klausen, P., and Claesson, M. H. Ligation of major histocompatibility complex (MHC) class I molecules on human T cells induces cell death through PI-3 kinase-induced c-Jun NH2-terminal kinase activity: a novel apoptotic pathway distinct from Fas-induced apoptosis. J. Cell Biol., 139: 1523-1531, 1997.
28. Gulbins, E., Brenner, B., Koppenhoefer, U., Linderkamp, O., and Lang, F. Fas or ceramine induce apoptosis by Ras-regulated phosphoinositide-3-kinase activation. J. Leukocyte Biol., 63: 253-263, 1998.
29. Chung, L. W. K. LNCaP human prostate cancer progression model. Urologic Oncol., 2: 126-128, 1996.
30. Gleave, M. E., Hsieh, J-T., Wu, H-C., von Eschenbach, A. C., and Chung, L. W. K. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res., 52: 1598-1605, 1992.
31. Thalmann, G. N. Anezinis, P. E., Chang, S-M., Zhau, H. E., Kim, E. E., Hopwood, V. L., Pathak, S., von Eschenbach, A. C., and Chung, L. W. K. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res., 54: 2577-2581, 1994.
32. Umekita, Y., Hiipakka, R. A., Kokontis, J. M., and Liao, S. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc. Natl. Acad. Sci. USA, 93: 11802-11807, 1996.
33. Wu, T. T., Sikes, R. A., Cui, Q., Thalmann, G. N., Kao, C., Murphy, C. F., Yang, H., Zhau, H. E., Balian, G., and Chung, L. W. K. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int. J. Cancer, 77: 887-894, 1998.
34. Bang, Y. J., Pirnia, F., Fang, W. G., Kang, W. K., Sartor, O., Whitesell, L., Ha, M. J., Tsokos, M., Sheahan, M. D., Nguyen, P., et al. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc. Natl. Acad. Sci. USA, 91: 5330-5334, 1994.
35. Hsieh, T. C., Xu, W., and Chiao, J. W. Growth regulation and cellular changes during differentiation of human prostatic cancer LNCaP cells as induced by T lymphocyte-conditioned medium. Exp. Cell Res., 218: 137-143, 1995.
36. Qiu, Y., Robinson, D., Pretlow, T. G., and Kung, H. J. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3′-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc. Natl. Acad. Sci. USA, 95: 3644-3649, 1998.
37. di Sant' Agnese, P. A. Neuroendocrine differentiation in prostatic carcinoma: an update. Prostate, 8: 74-79, 1998.
38. Philpott, K. L., McCarthy, M. J., Klippel, A., and Rubin, L. L. Activated phosphatidylinositol 3-kinase and Akt kinase promote survival of superior cervical neurons. J. Cell Biol., 139: 809-815, 1998.
39. Vemuri, G. S., and McMorris, F. A. Oligodendrocytes and their precursors require phosphatidylinositol 3-kinase signaling for survival. Development (Camb.), 122: 2529-2537, 1996.
40. McConkey, D. J., Greene, G., and Pettaway, C. A. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res., 56: 5594-5599, 1996.
41. Qiu, Y., Ravi, L., and Kung, H. J. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature (Lond.), 393: 83-85, 1998.
42. Freeman, M. R. Schneck, F. X., Gagnon, M., Corless, C., Soker, S., Niknejad, K., Peoples, G. E., and Klagsbrun, M. Peripheral blood T lymphocytes and T cells infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res., 55: 4140-4145, 1995.